Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 1
1983 1
1984 1
1985 1
1989 2
1990 2
1991 2
1993 3
1995 2
1996 3
1997 5
1998 3
1999 5
2000 2
2001 3
2002 5
2003 4
2004 4
2005 5
2006 6
2007 6
2008 5
2009 10
2010 15
2011 15
2012 13
2013 15
2014 8
2015 14
2016 14
2017 19
2018 18
2019 18
2020 29
2021 24
2022 23
2023 25
2024 31
2025 43
2026 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

369 results

Results by year

Filters applied: . Clear all
Page 1
Aspartame carcinogenic potential revealed through network toxicology and molecular docking insights.
Chen D, Hou X. Chen D, et al. Sci Rep. 2024 May 20;14(1):11492. doi: 10.1038/s41598-024-62461-w. Sci Rep. 2024. PMID: 38769413 Free PMC article.
In recent years, its safety issues, particularly the potential carcinogenic risk, have garnered widespread attention. ...The study introduces a fresh scientific method for evaluating the safety of food enhancers and provides a theoretical foundation for shaping publ …
In recent years, its safety issues, particularly the potential carcinogenic risk, have garnered widespread attention. ...The study in …
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Brennan B, Kirton L, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Fenwick N, Strauss S, Moroz V, Whelan J, Wheatley K. Brennan B, et al. Lancet. 2022 Oct 29;400(10362):1513-1521. doi: 10.1016/S0140-6736(22)01790-1. Lancet. 2022. PMID: 36522207 Clinical Trial.
Patients who received at least one dose of study treatment were considered in the safety analysis. The trial was registered with EudraCT, 2012-002107-17, and ISRCTN, 54540667. ...Febrile neutropenia as a grade 3-5 treatment toxicity occurred in 234 (74%) patients in …
Patients who received at least one dose of study treatment were considered in the safety analysis. The trial was registered with Eudr …
SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine.
Wobst HJ, Viader A, Muncipinto G, Hollibaugh R, van Kalken D, Burkhart CT, Cantin SM, Bates RM, Regimbald-Dumas Y, Gross L, Antalek MT, Zweig JE, Wu F, Rettenmaier TJ, Labenski MT, Pullen N, Blanchette HS, Henderson JL, Weng HH, Vaughn TA, Brown DG, Throup JP, Barrish JC. Wobst HJ, et al. JCI Insight. 2024 Nov 8;9(21):e182876. doi: 10.1172/jci.insight.182876. JCI Insight. 2024. PMID: 39513367 Free PMC article. Clinical Trial.
BACKGROUNDThe toxic accumulation of phenylalanine (Phe) in the brain underlies the neurological presentation of phenylketonuria (PKU). ...The primary objective of the study was safety. Secondary objectives included pharmacokinetic and pharmacodynamic studies. …
BACKGROUNDThe toxic accumulation of phenylalanine (Phe) in the brain underlies the neurological presentation of phenylketonuri …
Aspartame and ischemic stroke: unraveling the molecular link through network toxicology and molecular docking analysis.
Zhang T, Wang T, Yu K, Huang C, Bao K. Zhang T, et al. Sci Rep. 2025 Jul 4;15(1):23871. doi: 10.1038/s41598-025-08898-z. Sci Rep. 2025. PMID: 40615604 Free PMC article.
Aspartame, a widely used artificial sweetener, remains controversial due to neurotoxic risks from its metabolites-phenylalanine, aspartic acid, and methanol. While epidemiological studies link artificial sweeteners to cerebrovascular disease, the molecular mechanisms conne …
Aspartame, a widely used artificial sweetener, remains controversial due to neurotoxic risks from its metabolites-phenylalanine, aspa …
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.
Mateos MV, San-Miguel J, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Yoon SS, Iosava G, Fujisaki T, Garg M, Ngo M, Katz EG, Krevvata M, Bolyard K, Carson R, Borgsten F, Dimopoulos MA. Mateos MV, et al. Lancet Oncol. 2025 May;26(5):596-608. doi: 10.1016/S1470-2045(25)00018-X. Epub 2025 Apr 9. Lancet Oncol. 2025. PMID: 40220771 Clinical Trial.
The safety population, consisting of patients who received any dose of study treatment, was used in safety analyses. ...INTERPRETATION: With more than 7 years of follow-up, D-VMP continued to elicit clinical benefits in transplant-ineligible patients with newly diag …
The safety population, consisting of patients who received any dose of study treatment, was used in safety analyses. ...INTERP …
Revisiting the safety of aspartame.
Choudhary AK, Pretorius E. Choudhary AK, et al. Nutr Rev. 2017 Sep 1;75(9):718-730. doi: 10.1093/nutrit/nux035. Nutr Rev. 2017. PMID: 28938797 Review.
Since aspartame consumption is on the rise, the safety of this sweetener should be revisited. Most of the literature available on the safety of aspartame is included in this review. Safety studies are based primarily on animal models, as data from human studi …
Since aspartame consumption is on the rise, the safety of this sweetener should be revisited. Most of the literature available on the …
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M. Gay F, et al. Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. Lancet Oncol. 2021. PMID: 34774221 Free article. Clinical Trial.
BACKGROUND: Bortezomib-based induction followed by high-dose melphalan (200 mg/m(2)) and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with lenalidomide alone is the current standard of care for young and fit patients with newly diagnosed multiple m …
BACKGROUND: Bortezomib-based induction followed by high-dose melphalan (200 mg/m(2)) and autologous stem-cell transplantation (MEL200-ASCT) …
Optimizing high dose melphalan.
Shah G, Giralt S, Dahi P. Shah G, et al. Blood Rev. 2024 Mar;64:101162. doi: 10.1016/j.blre.2023.101162. Epub 2023 Dec 10. Blood Rev. 2024. PMID: 38097487 Free PMC article. Review.
In the context of hematopoietic cell transplantation (HCT), high dose melphalan (HDM) is the most common conditioning regimen used due to its potent anti-myeloma effects and manageable toxicities. Common toxicities associated with HDM include myelosuppression, gastr …
In the context of hematopoietic cell transplantation (HCT), high dose melphalan (HDM) is the most common conditioning regimen used due to it …
Aspartame: review of safety.
Butchko HH, Stargel WW, Comer CP, Mayhew DA, Benninger C, Blackburn GL, de Sonneville LM, Geha RS, Hertelendy Z, Koestner A, Leon AS, Liepa GU, McMartin KE, Mendenhall CL, Munro IC, Novotny EJ, Renwick AG, Schiffman SS, Schomer DL, Shaywitz BA, Spiers PA, Tephly TR, Thomas JA, Trefz FK. Butchko HH, et al. Regul Toxicol Pharmacol. 2002 Apr;35(2 Pt 2):S1-93. doi: 10.1006/rtph.2002.1542. Regul Toxicol Pharmacol. 2002. PMID: 12180494 Review.
Its safety was further confirmed through studies in several human subpopulations, including healthy infants, children, adolescents, and adults; obese individuals; diabetics; lactating women; and individuals heterozygous (PKUH) for the genetic disease phenylketonuria (PKU) …
Its safety was further confirmed through studies in several human subpopulations, including healthy infants, children, adolescents, a …
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.
Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, de la Calle VG, Oriol A, Ocio EM, Rosiñol L, Montes YG, Bargay J, García MEG, Lakhwani S, Payer AR, Suarez-Cabrera A, Blanchard MJ, Garzón S, Montero FC, Cabañas V, de Oteyza JP, Gironella M, Martinez-Lopez J, Casasús AIT, Delgado-Beltrán MP, Prieto E, Lahuerta JJ, Bladé J, San-Miguel J. Mateos MV, et al. Lancet Haematol. 2025 Aug;12(8):e588-e598. doi: 10.1016/S2352-3026(25)00143-7. Lancet Haematol. 2025. PMID: 40769684 Clinical Trial.
BACKGROUND: Triplet and quadruplet regimens based on bortezomib, melphalan and prednisone (VMP) and lenalidomide and dexamethasone (Rd) with anti-CD38 antibodies are potential treatments for transplant-ineligible patients with newly diagnosed multiple myeloma. However, the high r …
BACKGROUND: Triplet and quadruplet regimens based on bortezomib, melphalan and prednisone (VMP) and lenalidomide and dexamethasone (Rd) with …
369 results